KINS
Microbiome-based supplements, skincare, and clinical services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | N/A | Series C | |
| Total Funding | 000k | ||
KINS is a healthcare company focused on the microbiome, providing products and services for humans and pets. Founded in December 2018 by Dr. Yutaka Shimokawa, the company aims to make "bacterial care" a standard practice for managing health and beauty. Shimokawa, a dentist, was inspired during his tenure as a hospital director, where he witnessed significant health improvements in over 2,500 patients with chronic conditions through lifestyle changes and microbiome management. This experience led him to establish KINS to explore the potential of bacterial care for fundamental treatment.
The company operates a multifaceted business model that integrates consumer healthcare, clinical services, and medical research. The consumer division offers a range of direct-to-consumer (D2C) products, including supplements and skincare lines for gut, skin, and scalp health, which are developed based on research from their in-house lab. This is complemented by a subscription service that includes concierge support via LINE for personalized advice. The clinical arm includes veterinary hospitals in Japan and a human-focused clinic in Singapore specializing in conditions like acne, which also serve as a source for collecting clinical data on bacteria.
This data, along with data from over 20,000 samples in their proprietary bacteria bank platform, fuels their R&D at the KINS LAB. This research and development function focuses on creating proprietary bacteria and raw materials for its products and for B2B clients in the food, cosmetics, and pharmaceutical industries. Ultimately, KINS aims to develop microbiome-based pharmaceuticals. The company has expanded its operations to Taiwan and Singapore and has secured significant funding from various corporate venture capital funds to enhance its B2C and B2B growth.
Keywords: microbiome, skincare, supplements, probiotics, healthcare, D2C, biotechnology, clinical research, veterinary, gut health, bacterial care, Japanese beauty, Yutaka Shimokawa, consumer healthcare, microbiome therapy, wellness, preventative medicine, chronic disease, health-tech, life sciences